Cancer Discov. 2023 Dec 12;13(12):OF9. doi: 10.1158/2159-8290.CD-ND2023-0012.
Data from three phase III trials-PAPILLON, MARIPOSA, and MARIPOSA-2-highlight amivantamab, an EGFR-MET bispecific antibody, as a potential contender as a standard treatment for EGFR-mutant non-small cell lung cancer. Amivantamab paired with chemotherapy is a superior first-line option for patients with exon 20-mutated disease. Beyond this subset, compared with standard osimertinib, the combination with or without lazertinib also boosted progression-free survival, albeit at the cost of added toxicity.
三项III期试验（PAPILLON、MARIPOSA和MARIPOSA-2）的数据表明，EGFR-MET双特异性抗体阿米万他单抗有望成为EGFR突变型非小细胞肺癌的标准治疗药物。对于20号外显子突变的患者，阿米万他单抗联合化疗是更好的一线治疗选择。在这一亚组之外，与标准的奥希替尼相比，联合或不联合拉泽替尼的方案也提高了无进展生存期，尽管代价是毒性增加。
